This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Craig B. Thompson, M.D., President and Chief Executive Officer, Memorial Sloan-Kettering Cancer Center, to its Board of Directors. Dr. Thompson’s extensive experience with both global pharmaceutical companies and leading academic institutions in the fields of cancer biology and immunology will provide Charles River with a unique combination of expertise.
“Dr. Thompson’s experience overseeing oncology and immunology research, and particularly his focus on translational medicine, will enhance the expertise of Charles River’s Board,” said James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories. “His understanding of the strategic use of outsourcing—whether by global pharmaceutical companies, biotechnology companies, or academic and government institutions—will enable us to strengthen our position as the partner of choice for our clients’ early-stage drug development programs.”
Prior to joining Memorial Sloan-Kettering Cancer Center in 2010, Dr. Thompson held various roles at the University of Pennsylvania. He currently serves as a member of the Medical Advisory Board of the Howard Hughes Medical Institute; on the Board of Directors of Merck & Co., Inc.; as a member of the Lasker Prize Jury; and as Associate Editor of the journals
Cell, Immunity, and
Cancer Cell. Dr. Thompson holds a number of patents related to immunotherapy and apoptosis, and is a founder of three biotechnology companies. He is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation, and the American Association of Physicians. Dr. Thompson has published more than 350 peer-reviewed manuscripts and more than 85 reviews.
“I am pleased to join Charles River’s Board and to work with this outstanding team. I look forward to contributing to the future success and growth of this recognized global leader,” said Dr. Thompson.